We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Brain Perfusion in Pantothenate Kinase-associated Neurodegeneration (PKAN)

This study is currently recruiting participants.
Verified September 2016 by Susan J. Hayflick, Oregon Health & Science University
Sponsor:
ClinicalTrials.gov Identifier:
NCT01838018
First Posted: April 23, 2013
Last Update Posted: September 28, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborators:
Oregon Health and Science University
Oregon Clinical and Translational Research Institute
Information provided by (Responsible Party):
Susan J. Hayflick, Oregon Health & Science University
  Purpose
The purpose of this study is to learn whether blood flow in the brain is normal in people with pantothenate kinase-associated neurodegeneration (PKAN). Specifically, preliminary data suggest a region of the brain called the globus pallidus (GP), a key region affected by PKAN, may have reduced blood flow. Standard MRI and perfusion scanning techniques will be used to learn about cerebral blood flow in the globus pallidus and compare it to blood flow in other brain regions as well as to healthy controls.

Condition
Pantothenate Kinase-associated Neurodegeneration (PKAN)

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Brain Perfusion in Pantothenate Kinase-Associated Neurodegeneration (PKAN)

Resource links provided by NLM:


Further study details as provided by Susan J. Hayflick, Oregon Health & Science University:

Primary Outcome Measures:
  • ASL-derived cerebral blood flow(CBF) [ Time Frame: Single MRI ]
    The unit of analyses will be the subject and the primary comparison will be the globus pallidus CBF between PKAN and healthy controls.


Estimated Enrollment: 12
Study Start Date: April 2013
Estimated Study Completion Date: October 2017
Estimated Primary Completion Date: October 2017 (Final data collection date for primary outcome measure)
Groups/Cohorts
PKAN
This group consists of individuals diagnosed with PKAN using a combination of MRI and PANK2 gene sequencing.
Healthy volunteers
This is a control group of healthy volunteers, matched with the PKAN group for age and sex.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   7 Years to 75 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
The PKAN group consists of individuals in the United States diagnosed with PKAN.
Criteria

Inclusion Criteria:

  • diagnosis of PKAN confirmed by MRI and gene testing
  • able to undergo MRI for approximately 1 hour without sedation

Exclusion Criteria:

  • deep brain stimulators or other conditions that warrant avoidance of a strong magnetic field
  • previous reaction to gadolinium (Gd) contrast agent
  • acute or chronic kidney dysfunction
  • pregnant and/or nursing at time of study
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01838018


Contacts
Contact: Allison M Gregory, MS 503-494-4344 gregorya@ohsu.edu

Locations
United States, Oregon
Oregon Health & Science University Recruiting
Portland, Oregon, United States, 97239
Contact: Allison M Gregory, MS    503-494-4344    gregorya@ohsu.edu   
Principal Investigator: Susan J Hayflick, MD         
Sponsors and Collaborators
Susan J. Hayflick
Oregon Health and Science University
Oregon Clinical and Translational Research Institute
Investigators
Principal Investigator: Susan J Hayflick, MD Oregon Health and Science University
  More Information

Additional Information:
Responsible Party: Susan J. Hayflick, Professor & Chair, Molecular & Medical Genetics, Oregon Health & Science University
ClinicalTrials.gov Identifier: NCT01838018     History of Changes
Other Study ID Numbers: 8777
First Submitted: April 18, 2013
First Posted: April 23, 2013
Last Update Posted: September 28, 2016
Last Verified: September 2016

Keywords provided by Susan J. Hayflick, Oregon Health & Science University:
PKAN
brain iron
NBIA
neurodegeneration with brain iron accumulation
Hallervorden Spatz Syndrome

Additional relevant MeSH terms:
Pantothenate Kinase-Associated Neurodegeneration
Nerve Degeneration
Pathologic Processes
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neuroaxonal Dystrophies
Movement Disorders
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn